Skip to main
AMGN
AMGN logo

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 0%
Buy 25%
Hold 67%
Sell 8%
Strong Sell 0%

Bulls say

Amgen has demonstrated substantial growth in sales, with a notable 40% increase in the third quarter of 2025 compared to the same period in 2024, driven by the success of key products such as Repatha and Tezspire, which both recorded impressive year-over-year increases in new prescriptions. The company is also increasing its investment in research and development, with a projected growth of over 20% in R&D expenditure for 2025, indicating a strong commitment to innovation and expansion. Additionally, Amgen raised its FY25 revenue guidance to a range of $35.8 billion to $36.6 billion, reflecting the ongoing strength and performance of its established franchises and recent acquisitions.

Bears say

Amgen's revenue growth is projected to be only around 1% in 2026 compared to 2025, largely due to significant anticipated sales declines of approximately 28% for Prolia and 39% for Xgeva. The company's research and development spending is expected to grow more mutedly relative to 2025, indicating constraints on future innovation and competitive positioning. Additionally, despite the potential of emerging products like MariTide and olpasiran, uncertainty surrounding their ability to compensate for declining revenues from established products creates a challenging outlook, particularly with impending loss of exclusivity for key franchises.

Amgen (AMGN) has been analyzed by 12 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 25% recommend Buy, 67% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 12 analysts, Amgen (AMGN) has a Hold consensus rating as of Dec 11, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $318.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $318.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.